Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 18 peer-reviewed journal articles Updated
Medical Genetics

The Biology of CGL: Subtypes and Diagnosis

At a Glance

Congenital generalized lipodystrophy (CGL) causes near-total loss of body fat from birth because of changes in genes that support fat cells. Genetic testing identifies CGL1–CGL4 and helps doctors anticipate subtype-specific concerns such as bone cysts, muscle weakness, or heart rhythm problems.

To understand your child’s diagnosis, it is helpful to look at how the body’s “fuel tanks” are built. In Congenital Generalized Lipodystrophy (CGL), the primary issue is a failure of the adipocytes (fat cells). These cells are meant to safely store energy as fat. When they fail, the fat has nowhere to go, leading to a chain reaction of metabolic challenges [1][2].

The Four Subtypes of CGL

Researchers have identified four main genetic versions of CGL. Each is caused by a change in a different gene that is essential for building or maintaining fat cells. While they all result in a near-total loss of body fat from birth, they each have unique “signatures” [3][4]. Note that symptoms can vary widely, and these associations are not guaranteed for every child.

Subtype Gene Key Features & Differences
CGL1 AGPAT2 Often preserves small amounts of fat in the scalp, earlobes, palms, and soles. It is frequently associated with the development of bone cysts (small pockets in the bone) after puberty [5][6].
CGL2 BSCL2 Generally the most common and often more severe. It typically involves a more complete loss of fat, including from the palms and soles. There is a higher risk of intellectual disability and earlier onset of diabetes [6][7]. Cardiac disease is also a known risk in this subtype.
CGL3 CAV1 A very rare form. It involves extreme fat loss, and some cases have noted a neonatal progeroid (aged) appearance [8].
CGL4 PTRF Distinguished by myopathy (muscle weakness), high levels of muscle enzymes in the blood, and heart rhythm issues. It may also be linked to pyloric stenosis, a narrowing of the stomach exit in infants [9][10].

Why the Fat Disappears

The biological “glitch” in CGL happens at the cellular level. Depending on the subtype, the body either cannot make new fat cells or cannot keep existing ones healthy [3][4].

  • Adipocyte Failure: In CGL1, an enzyme needed to create the building blocks of fat is missing. In CGL2, a protein called seipin fails to manage the fat droplets inside cells, causing the cells to essentially break down or fail to mature [11][2].
  • Ectopic Fat: Because the “fuel tanks” (fat cells) are broken, the fat you eat—and the fat your body makes—spills over into places it should never be. This is called ectopic lipid deposition. It primarily builds up in the liver and muscles, which can make the liver enlarge and the muscles look very prominent [1][12].
  • Hypoleptinemia: Fat cells produce a hormone called leptin, which tells the brain the body has enough energy and isn’t hungry. Because children with CGL have almost no fat cells, their leptin levels are usually profoundly low. This deficiency is a major contributor to a constant, intense hunger that is very difficult for parents to manage [1][13].

Ruling Out Other Conditions

When a child appears to have very little body fat, doctors must perform a differential diagnosis to ensure they aren’t looking at a different condition. CGL is often distinguished from others by its presence at birth and its specific genetic markers [14].

  • Acquired Generalized Lipodystrophy (AGL): Unlike CGL, this starts later in childhood or adulthood, often after an illness. It is usually an autoimmune issue rather than a genetic one [15].
  • Familial Partial Lipodystrophy (FPLD): In this group of conditions, fat is only lost from certain parts of the body (like the arms and legs), while fat may actually increase in the face and neck. This usually becomes noticeable during puberty, not at birth [16].
  • Diencephalic Syndrome: This is a rare condition caused by a brain tumor (like a pilocytic astrocytoma) in the area of the brain that controls growth. It can cause an infant to look very thin and lose fat. Distinguishing this requires careful neurological exams, growth tracking, brain imaging, and genetic testing, rather than assuming it based on metabolic labs alone [17].

By using comprehensive genetic testing, your care team can identify the exact subtype of CGL. While body-composition scans or MRI can help map fat distribution, MRI does not confirm the gene subtype itself and is not routinely required for every infant [5][18]. Understanding the genetics is vital because it helps predict which “extra” symptoms—like bone cysts in CGL1 or heart rhythm issues in CGL4—need the most attention as your child grows.

Common questions in this guide

What are the four congenital generalized lipodystrophy subtypes?
Four main CGL subtypes are recognized: CGL1 is linked to AGPAT2, CGL2 to BSCL2, CGL3 to CAV1, and CGL4 to PTRF. All can cause near-total loss of body fat from birth, but associated features differ and do not occur in every child.
How is congenital generalized lipodystrophy diagnosed?
Doctors use a child’s appearance and medical history, physical examination, and genetic testing to evaluate congenital generalized lipodystrophy. Comprehensive genetic testing can identify the responsible gene and subtype. Body-composition scans or MRI may show where fat is distributed, but MRI alone cannot confirm the gene subtype and is not routinely needed for every infant.
How is CGL different from other generalized or partial lipodystrophies?
CGL is usually present at birth and causes near-total loss of body fat because of an inherited gene change. Acquired generalized lipodystrophy usually begins later and is often related to autoimmunity, while familial partial lipodystrophy affects only some body regions and often becomes apparent around puberty.
Why are leptin levels and hunger important in CGL?
Leptin is a hormone made by fat cells that helps signal energy stores and hunger to the brain. Because children with CGL have very few fat cells, leptin levels are usually very low, which can contribute to constant, intense hunger and abnormal energy regulation.
Which CGL subtype is linked to muscle weakness and heart-rhythm problems?
CGL4 is associated with PTRF changes and may cause muscle weakness, high muscle-enzyme levels, and heart-rhythm problems; pyloric stenosis can also occur. CGL2 is also associated with a higher risk of cardiac disease, so the child’s exact gene result helps guide monitoring.
What monitoring might a child with CGL need?
Monitoring depends on the subtype and the child’s findings. The care team may discuss bone evaluation for CGL1, heart-rhythm monitoring for cardiac risk, creatine kinase testing when CGL4 is suspected, and developmental or neurologic assessment when concerns are present.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Which specific genetic subtype (CGL1, 2, 3, or 4) does my child have, and what was the exact gene change found?
  2. 2.Has my child's creatine kinase (CK) level been tested to look for signs of myopathy, especially if CGL4 is suspected?
  3. 3.Given the subtype, should we be doing regular heart rhythm monitoring or bone scans?
  4. 4.Does my child’s physical examination show any 'preserved' fat in the palms or soles, and what does that tell us about their type of CGL?
  5. 5.Are there any signs of intellectual disability or neurological issues we should be watching for based on their genetic result?
  6. 6.How do my child’s current leptin levels compare to what is expected, and how does that affect their hunger and metabolism?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (18)
  1. 1

    Eating behaviour in contrasting adiposity phenotypes: Monogenic obesity and congenital generalized lipodystrophy.

    Santos JL, Cortés VA

    Obesity reviews : an official journal of the International Association for the Study of Obesity 2021; (22(1)):e13114 doi:10.1111/obr.13114.

    PMID: 33030294
  2. 2

    "Seipin mediates Perilipin-1 recruitment to lipid droplets to preserve human adipocyte identity".

    Zhong D, Stavrakaki I, Desai A, et al.

    bioRxiv : the preprint server for biology 2025; doi:10.1101/2025.11.09.687445.

    PMID: 41292895
  3. 3

    Congenital generalized lipodystrophies--new insights into metabolic dysfunction.

    Patni N, Garg A

    Nature reviews. Endocrinology 2015; (11(9)):522-34 doi:10.1038/nrendo.2015.123.

    PMID: 26239609
  4. 4

    Maladaptative Autophagy Impairs Adipose Function in Congenital Generalized Lipodystrophy due to Cavin-1 Deficiency.

    Salle-Teyssières L, Auclair M, Terro F, et al.

    The Journal of clinical endocrinology and metabolism 2016; (101(7)):2892-904 doi:10.1210/jc.2016-1086.

    PMID: 27144934
  5. 5

    Determining residual adipose tissue characteristics with MRI in patients with various subtypes of lipodystrophy.

    Altay C, Seçil M, Demir T, et al.

    Diagnostic and interventional radiology (Ankara, Turkey) 2017; (23(6)):428-434 doi:10.5152/dir.2017.17019.

    PMID: 29044029
  6. 6

    Genotype-phenotype correlations of Berardinelli-Seip congenital lipodystrophy and novel candidate genes prediction.

    Ren M, Shi J, Jia J, et al.

    Orphanet journal of rare diseases 2020; (15(1)):108 doi:10.1186/s13023-020-01383-y.

    PMID: 32349771
  7. 7

    Monogenic forms of lipodystrophic syndromes: diagnosis, detection, and practical management considerations from clinical cases.

    Vatier C, Vantyghem MC, Storey C, et al.

    Current medical research and opinion 2019; (35(3)):543-552 doi:10.1080/03007995.2018.1533459.

    PMID: 30296183
  8. 8

    Biallelic CAV1 null variants induce congenital generalized lipodystrophy with achalasia.

    Karhan AN, Zammouri J, Auclair M, et al.

    European journal of endocrinology 2021; (185(6)):841-854 doi:10.1530/EJE-21-0915.

    PMID: 34643546
  9. 9

    Metabolic and other morbid complications in congenital generalized lipodystrophy type 4.

    Akinci G, Alyaarubi S, Patni N, et al.

    American journal of medical genetics. Part A 2024; (194(6)):e63533 doi:10.1002/ajmg.a.63533.

    PMID: 38234231
  10. 10

    A new mutation in the CAVIN1/PTRF gene in two siblings with congenital generalized lipodystrophy type 4: case reports and review of the literature.

    Mancioppi V, Daffara T, Romanisio M, et al.

    Frontiers in endocrinology 2023; (14()):1212729 doi:10.3389/fendo.2023.1212729.

    PMID: 37501786
  11. 11

    Congenital Generalized Lipoatrophy (Berardinelli-Seip Syndrome) Type 1: Description of Novel AGPAT2 Homozygous Variants Showing the Highly Heterogeneous Presentation of the Disease.

    Ceccarini G, Magno S, Pelosini C, et al.

    Frontiers in endocrinology 2020; (11()):39 doi:10.3389/fendo.2020.00039.

    PMID: 32117065
  12. 12

    Berardinelli-Seip Congenital Lipodystrophy Discovered Following a STEMI Event.

    Beires F, Greenfield H, Brito da Silva J, et al.

    European journal of case reports in internal medicine 2022; (9(12)):003658 doi:10.12890/2022_003658.

    PMID: 36632537
  13. 13

    Metreleptin Treatment in Three Patients with Generalized Lipodystrophy.

    Musso C, Major ML, Andres E, Simha V

    Clinical medicine insights. Case reports 2016; (9()):123-127 doi:10.4137/CCRep.S40196.

    PMID: 28096701
  14. 14

    Seipin-linked congenital generalized lipodystrophy type 2: a rare case with multiple lytic and pseudo-osteopoikilosis lesions.

    Yamamoto A, Kusakabe T, Sato K, et al.

    Acta radiologica open 2019; (8(12)):2058460119892407 doi:10.1177/2058460119892407.

    PMID: 31853371
  15. 15

    Autoantibodies Against Perilipin 1 as a Cause of Acquired Generalized Lipodystrophy.

    Corvillo F, Aparicio V, López-Lera A, et al.

    Frontiers in immunology 2018; (9()):2142 doi:10.3389/fimmu.2018.02142.

    PMID: 30283460
  16. 16

    Clinical Features and Management of Non-HIV-Related Lipodystrophy in Children: A Systematic Review.

    Gupta N, Asi N, Farah W, et al.

    The Journal of clinical endocrinology and metabolism 2017; (102(2)):363-374 doi:10.1210/jc.2016-2271.

    PMID: 27967300
  17. 17

    A Novel Syndrome of Generalized Lipodystrophy Associated With Pilocytic Astrocytoma.

    Patni N, Alves C, von Schnurbein J, et al.

    The Journal of clinical endocrinology and metabolism 2015; (100(10)):3603-6 doi:10.1210/jc.2015-2476.

    PMID: 26252356
  18. 18

    The Diagnosis and Management of Lipodystrophy Syndromes: A Multi-Society Practice Guideline.

    Brown RJ, Araujo-Vilar D, Cheung PT, et al.

    The Journal of clinical endocrinology and metabolism 2016; (101(12)):4500-4511 doi:10.1210/jc.2016-2466.

    PMID: 27710244

This page explains the genetic subtypes and diagnosis of congenital generalized lipodystrophy for informational purposes only and does not constitute medical advice. Your child’s genetics and medical teams should interpret test results and recommend monitoring for their specific situation.

Get notified when new evidence is published on Congenital generalized lipodystrophy.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.